Total Voting Rights Update

RNS Number : 7488K
Oxford Biomedica PLC
30 June 2014


30 June 2014



Total Voting Rights Update


In accordance with the FCA's Disclosure and Transparency Rules, Oxford BioMedica plc (LSE:OXB) confirms that the Company's issued share capital consists of 2,494,584,919 ordinary shares of 1p each, all with voting rights.  No shares are held in treasury.


This figure may be used by shareholders as the denominator for the calculation by which they will determine whether they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.






For further information, please contact:


Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Tim Watts, Chief Financial Officer




Tel: +44 (0)1865 783 000



Media Enquiries:

Mary-Jane Elliott/Emma Thompson/Matthew Neal

Consilium Strategic Communications

Tel: +44 (0)20 3709 5700


Notes to editors

Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at and


This information is provided by RNS
The company news service from the London Stock Exchange